Clinical Trials Directory

Trials / Completed

CompletedNCT01712100

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Irbesartan Tablets Under Fed Conditions

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
34 (actual)
Sponsor
Roxane Laboratories · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The objective of this study was to prove the bioequivalence of Roxane Laboratories' Irbesartan 300 mg Tablets under fed conditions.

Conditions

Interventions

TypeNameDescription
DRUGIrbesartan
DRUGAvapro

Timeline

Start date
2007-08-01
Primary completion
2007-08-01
Completion
2007-08-01
First posted
2012-10-23
Last updated
2018-01-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01712100. Inclusion in this directory is not an endorsement.